MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock and...
$31,657,066
something is missing
$2,251,380
Cash provided by
financing activities
$31,657,069
(1306.12%↑ Y/Y)
Canceled cashflow
$2,251,377
Net (decrease)
increase in cash and cash...
$25,646,892
(309.40%↑ Y/Y)
Canceled cashflow
$6,010,177
Proceeds from exercise of
warrants, net of issuance...
-$2,251,377
(-200.00%↓ Y/Y)
Accounts payable and
accrued liabilities
$493,855
(116.99%↑ Y/Y)
Stock-based compensation
expense
$428,306
(-62.03%↓ Y/Y)
Change in operating
lease right-of-use...
$49,450
(35.01%↑ Y/Y)
Prepaid expenses and
other current assets
-$42,593
(-106.93%↓ Y/Y)
Depreciation and
amortization
$35,524
(-68.24%↓ Y/Y)
Lease liability
$2,747
(106.78%↑ Y/Y)
Cash used in
operating activities
-$6,010,177
(58.55%↑ Y/Y)
Canceled cashflow
$1,052,475
Net loss
-$6,930,652
(42.49%↑ Y/Y)
Change in fair value of
warrants
-$132,000
(18.32%↑ Y/Y)
Back
Back
Cash Flow
Cellectar Biosciences, Inc. (CLRB)
Cellectar Biosciences, Inc. (CLRB)
source: myfinsight.com